Dosage ; see below
Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Arixtra | GlaxoSmithkline | GlaxoSmithKline | 2.5mg | 10 | Injection | per ampoule | KES 3,795.90 |
| Arixtra | GlaxoSmithkline | GlaxoSmithKline | 7.5mg | 10 | Injection | per ampoule | KES 6,537.90 |
| Fondaparinux More info | |
|---|---|
| Mode Of Action | Selective inhibitor of activated factor X that blocks both thrombin and thrombus formation |
| Drug Indication | Prevention of venous thromboembolism in high risk surgery; treatment of venous thromboembolism. |
| Contra-Indications | Active bleeding; creatinine clearance of less than 30mL/minute; acute bacterial endocarditis. |
| Side Effects | Bleeding; anaemia; thrombocytopenia; allergic reactions. |
| Dosage | Prevention of venous thromboembolism: 2.5mg SC OD for 5-9 days. The first dose is given 6 hours after closure and when haemostasis has been established and it may be continued for up to 31 days. Treatment of venous thromboembolism: <50kg, 5mg OD; 50-100kg, 7.5mg OD; > 100kg, 10mg OD. |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |